New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
04:55 EDTALKS, ALKS, RGDO, RGDO, LXRX, LXRX, ZIOP, ZIOP, RNA, RNA, AUXL, AUXL, XON, XON, SIGA, SIGA, GALE, GALE, MSTX, MSTXBiotech Industry Organization to hold a conference
16h Annual BIO CEO & Investor Conference is being held in New York on February 10-11.
News For ALKS;GALE;SIGA;XON;AUXL;RNA;ZIOP;LXRX;RGDO;MSTX From The Last 14 Days
Check below for free stories on ALKS;GALE;SIGA;XON;AUXL;RNA;ZIOP;LXRX;RGDO;MSTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 14, 2014
08:08 EDTMSTXMast Therapeutics announces positive data on MST-188
Subscribe for More Information
06:25 EDTLXRXLexicon to host conference call
Subscribe for More Information
06:10 EDTLXRXLexicon achieves positive results in Type 1 diabetes clinical trial
Lexicon Pharmaceuticals announced positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. In the placebo-controlled, double-blind, 28-day study, LX4211 reduced the total daily mealtime bolus insulin dose by 32% compared to 6% for placebo, while significantly improving glycemic control with a mean HbA1c reduction of 0.55% in the LX4211-treated group compared to a reduction of only 0.06% with placebo. This improvement was accompanied by significant improvement in the time spent in a glucose range of 70-180 mg/dl, a significant reduction in time in hyperglycemic range, and no increase in hypoglycemia. Multiple measures indicated that LX4211 treatment resulted in reduced variability in blood glucose levels. Overall, LX4211 was well tolerated with no discontinuations of study medication due to adverse events.
April 11, 2014
12:00 EDTRGDORegado Biosciences falls 15.8%
Subscribe for More Information
10:00 EDTRGDORegado Biosciences falls 17.6%
Subscribe for More Information
09:00 EDTRGDORegado Biosciences falls 16.3%
Subscribe for More Information
07:34 EDTRGDORegado Biosciences 10M share Secondary priced at $6.00
Jefferies, Deutsche Bank and Cowen acted as joint book running managers for the offering.
07:06 EDTAUXLVIVUS announces avanafil clinical data presentation
Subscribe for More Information
April 10, 2014
12:00 EDTRGDORegado Biosciences falls 13.3%
Subscribe for More Information
10:00 EDTALKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
10:00 EDTRGDORegado Biosciences falls 8.1%
Subscribe for More Information
05:55 EDTALKSAlkermes upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
April 9, 2014
07:49 EDTALKSAlkermes price target raised to $66 from $60 at Leerink
Subscribe for More Information
April 8, 2014
14:43 EDTALKSAlkermes price target rasied to $66 from $60 at Leerink
11:03 EDTZIOPZiopharm presents anti-tumor effects of Ad-RTS-mIL-12
Subscribe for More Information
09:00 EDTALKSAlkermes rises 7.4%
Alkermes is up 7.4%, or $3.03, to $44.13
07:47 EDTALKSAlkermes to host conference call
Subscribe for More Information
07:35 EDTLXRXNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
07:04 EDTALKSAlkermes announces phase 3 'positive' results from aripiprazole lauroxil study
Alkermes announced "positive" topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale total scores at week 12, compared to placebo, which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application to the U.S. Food and Drug Administration in 3Q14. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression-Improvement scale versus placebo at week 12. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Alkermes will present data from the phase 3 study at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.
April 7, 2014
12:00 EDTXONIntrexon falls 9.9%
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use